Primary sclerosing cholangitis

Canadian Journal of Gastroenterology

Volumn 22, Issue 8, 2008, Pages 689-698

  Silveira, Marina G ^a   Lindor, Keith D ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

Cholangiocarcinoma; Cholestasis; Diagnosis; Liver transplantation; Sclerosing cholangitis; Therapy

Indexed keywords

24 NORURSODEOXYCHOLIC ACID; 6 ALPHA ETHYLCHENODEOXYCHOLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTINEOPLASTIC AGENT; BUDESONIDE; CLADRIBINE; COLCHICINE; CYCLOSPORIN; DEOXYCHOLIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; ETANERCEPT; INFLIXIMAB; LOSARTAN; METHOTREXATE; METRONIDAZOLE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; PENICILLAMINE; PENTOXIFYLLINE; PIRFENIDONE; PREDNISOLONE; PREDNISONE; SILYMARIN; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

BILE DUCT CARCINOMA; BIOCHEMISTRY; CHOLANGIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; COLON CANCER; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SCREENING; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; RISK FACTOR; SEROLOGY;

EID: 54349108382     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/824168     Document Type: Review

References (158)

1. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;79:200-6.
2. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005;11:62-72.
3. Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007;102:1677-82.
4. Brandsaeter B, Friman S, Broome U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003;38:1176-83.
5. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: A review of its clinical features, cholangiography, and hepatic histology. Gut 1980;21:870-7.
6. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:553-62.
7. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-9.
8. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-23.
9. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
10. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and cutcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004;126:1929-30.
11. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children. A population-based analysis. Am J Gastroenterol 2007;102:1042-9.
12. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology 1989;10:430-6.
13. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-5.
14. Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G. Primary sclerosing cholangitis: Clinical presentation, natural history and prognostic variables: An Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996;8:685-91.
15. Olsson R, Broome U, Danielsson A, et al. Spontaneous course of symptoms in primary sclerosing cholangitis: Relationships with biochemical and histological features. Hepatogastroenterology 1999;46:136-41.
16. Balasubramaniam K, Wiesner RH, LaRusso NF. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 1988;95:1395-8.
17. Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004;99:502-8.
18. Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994;69:969-82.
19. Chapman RW, Cottone M, Selby WS, Shepherd HA, Sherlock S, Jewell DP. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 1986;27:86-91.
20. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepetology 1993;17:411-7.
21. Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: Prevalence, titre, specificity and IgG subclass. J Hepatol 1996;24:581-6.
22. Chapman RW. The enigma of anti-neutrophil antibodies in ulcerative colitis primary sclerosing cholangitis: Important genetic marker or epiphenomenon? Hepatology 1995;21:1473-4.
23. MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: Findings on cholangiography and pancreatography. Radiology 1983;149:39-44.
24. Bilbao MK, Dotter CT, Lee TG, Katon RM. Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases. Gastroenterology 1976;70:314-20.
25. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-18.
26. Talwalkar JA, Angulo P, Johnson CD, Petersen BT, Lindor KD. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004;40:39-45.
27. Etzel JP, Eng SC, Ko CW, et al. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc 2008;67:643-8.
28. Mehta SN, Reinhold C, Barkun AN. Magnetic resonance cholangiopancreatography. Gastrointest Endosc Clin N Am 1997;7:247-70.
29. Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: Diagnosis and management. Curr Gastroenterol Rep 2006;8:75-82.
30. Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989;13(Suppl 1):43-9.
31. Scheuer PJ. Ludwig Symposium on biliary disorders - part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998;73:179-83.
32. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003;98:1155-8.
33. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-12.
34. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-94.
35. Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2333-7.
36. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995;108:1199-203.
37. Duchini A, Younossi ZM, Saven A, Bordin GM, Knowles HJ, Pockros PJ. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000;31:292-6.
38. Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993;34:242-6.
39. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004;49:1-4.
40. Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008;42:522-6.
41. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494-9.
42. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005;100:308-12.
43. Sterling RK, Salvatori JJ, Luketic VA, et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther 2004;20:943-9.
44. Angulo P, Bharucha AE, Jorgensen RA, et al. Oral nicotine in treatment of primary sclerosing cholangitis: A pilot study. Dig Dis Sci 1999;44:602-7.
45. Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: Results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol 2001;13:171-5.
46. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036-42.
47. Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2338-42.
48. Angulo P, MacCarty RL, Sylvestre PB, et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002;47:157-61.
49. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: An open-label pilot study. Dig Dis Sci 2007 Oct 17.
50. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.
51. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007;27:451-3.
52. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991;86:57-61.
53. Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study. Am J Gastroenterol 1996;91:511-5.
54. van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000;95:2015-22.
55. Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999;131:943-6.
56. Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. Hepatology 2004;40:1379-86.
57. Silveira MG, Lindor KD. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. J Hepatol 2008;46:692-4.
58. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-5.
59. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
60. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-72.
61. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
62. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792-800.
63. Hoofnagle JH. Primary sclerosing cholangitis. Hepatology 2005;41:955.
64. Pall H, Zaman MM, Andersson C, Freedman SD. Decreased peroxisome proliferator activated receptor alpha is associated with bile duct injury in cystic fibrosis transmemberane conductance regulator -/- mice. J Pediatr Gastroenterol Nutr 2006;42:275-81.
65. Fickert P, Wagner M, Marschall HU, et al. 24-norursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130:465-81.
66. Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569-72.
67. Fiorucci S, Clerici C, Antonelli E, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005;313:604-12.
68. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004;127:1497-512.
69. Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: From structure to potential clinical applications. J Med Chem 2005;48:5383-403.
70. Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1059-66.
71. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325-32.
72. Linder S, Soderlund C. Endoscopic therapy in primary sclerosing cholangitis: Outcome of treatment and risk of cancer. Hepatogastroenterology 2001;48:387-92.
73. Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997;26:560-6.
74. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001;53:308-12.
75. Domajnko B, Ahrendt SA. Indications for non-transplant surgery in primary sclerosing cholangitis. HPB (Oxford) 2005;7:292-7.
76. McEntee G, Wiesner RH, Rosen C, Cooper J, Wahlstrom E. A comparative study of patients undergoing liver transplantation for primary sclerosing cholangitis and primary biliary cirrhosis. Transplant Proc 1991;23:1563-4.
77. Muiesan P, Shanmugam RP, Devlin J, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. Transplant Proc 1994;26:3574-6.
78. Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: Liver transplantation or biliary surgery. Surgery 1995;117:146-55.
79. Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995;22:451-7.
80. Ahrendt SA, Pitt HA, Kalloo AN, et al. Primary sclerosing cholangitis: Resect, dilate, or transplant? Ann Surg 1998;227:412-23.
81. Nashan B, Schlitt HJ, Tusch G, et al. Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation. Hepatology 1996;23:1105-11.
82. Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007;5:1313-5.
83. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS database. Liver Transpl 2004;10:886-97.
84. Merion RM. When is a patient too well and when is a patient too sick for a liver transplant? Liver Transpl 2004;10(10 Suppl 2):S69-73.
85. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: Summary of a workshop. Hepatology 2006;44:746-64.
86. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: A systematic review. Liver Transpl 2006;12:1813-24.
87. Khettry U, Keaveny A, Goldar-Najafi A, et al. Liver transplantation for primary sclerosing cholangitis: A long-term clinicopathologic study. Hum Pathol 2003;34:1127-36.
88. Brandsaeter B, Schrumpf E, Clausen OP, Abildgaard A, Hafsahl G, Bjoro K. Recurrent sclerosing cholangitis or ischemic bile duct lesions - a diagnostic challenge? Liver Transpl 2004;10:1073-4.
89. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999;29:1050-6.
90. Charatcharoenwitthaya P, Lindor KD. Recurrence of primary sclerosing cholangitis: What do we learn from several transplant centers? Liver Transpl 2008;14:130-2.
91. Jeyarajah DR, Netto GJ, Lee SP, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: Is chronic rejection part of the disease process? Transplantation 1998;66:1300-6.
92. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360:1943-4.
93. Tamura S, Sugawara Y, Kaneko J, Matsui Y, Togashi J, Makuuchi M. Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int 2007;27:86-94.
94. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:245-51.
95. Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: A magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005;11:1361-9.
96. Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003;9:727-32.
97. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:138-43.
98. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710-7.
99. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002;51:562-6.
100. Mendes FD, Kim WR, Pedersen R, Therneau T, Lindor KD. Mortality attributable to cholestatic liver disease in the United States. Hepatology 2008;47:1241-7.
101. Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology 1992;103:1893-901.
102. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 1997;25:1049-53.
103. Kim WR, Poterucha JJ, Wiesner RH, et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999;29:1643-8.
104. Talwalkar JA, Lindor KD. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:563-75.
105. Boberg KM, Rocca G, Egeland T, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002;35:652-7.
106. Helzberg JH, Petersen JM, Boyer JL. Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1987;92:1869-75.
107. Lindberg B, Arnelo U, Bergquist A, et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002;34:909-16.
108. Craig DA, MacCarty RL, Wiesner RH, Grambsch PM, LaRusso NF. Primary sclerosing cholangitis: Value of cholangiography in determining the prognosis. AJR Am J Roentgenol 1991;157:959-64.
109. Olsson RG, Asztely MS. Prognostic value of cholangiography in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1995;7:251-4.
110. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:5236.
111. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997;32:1042-5.
112. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.
113. Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004;40:815-22.
114. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007;19:487-91.
115. Lazaridis KN. Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008;47:8-10.
116. Kaya M, de Groen PC, Angulo P, et al. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: The Mayo Clinic experience. Am J Gastroenterol 2001;96:1164-9.
117. Yachimski P, Pratt DS. Cholangiocarcinoma: Natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008;42:178-90.
118. Prytz H, Keiding S, Bjornsson E, et al; Swedish Internal Medicine Liver Club. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006;44:1572-80.
119. Angulo P, Pearce DH, Johnson CD, et al. Magnetic resonance cholangiography in patients with biliary disease: Its role in primary sclerosing cholangitis. J Hepatol 2000;33:520-7.
120. Moreno Luna LE, Gores GJ. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl 2006;12(11 Suppl 2):S15-9.
121. Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001;33:1029-35.
122. Fevery J, Buchel O, Nevens F, Verslype C, Stroobants S, Van Steenbergen W. Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2005;43:358-60.
123. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004;8:90-7.
124. Zandrino F, Curone P, Benzi L, Ferretti ML, Musante F. MR versus multislice CT cholangiography in evaluating patients with obstruction of the biliary tract. Abdom Imaging 2005;3:77-85.
125. Park MS, Kim TK, Kim KW, et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: Findings at MRCP versus ERCP. Radiology 2004;233:234-40.
126. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-72.
127. Rabinovitz M, Zajko AB, Hassanein T, et al. Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: A study in 65 patients with bile duct strictures. Hepatology 1990;12:747-52.
128. Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006;45:568-74.
129. Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: Evaluation of specific cytomorphologic features and CA19-9 levels. Am J Clin Pathol 2005;124:355-60.
130. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004;99:1675-81.
131. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005;50:1734-40.
132. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21-5.
133. Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992;16:1290-9.
134. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-7.
135. Heimbach JK, Gores GJ, Nagorney DM, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: A new paradigm for liver and biliary malignancies? Surgery 2006;140:331-4.
136. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451-8; discussion 458-61.
137. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002;2:774-9.
138. Harnois DM, Gores GJ, Ludwig J, Steers JL, LaRusso NF, Wiesner RH. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 1997;27:512-6.
139. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: Evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol 2007;31:907-13.
140. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 1995;22:1404-8.
141. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41:522-5.
142. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
143. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
144. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;22:783-8.
145. Porayko MK, Wiesner RH, LaRusso NF, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990;93:1594-602.
146. Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: A comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005;100:1330-3.
147. Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut 2007;56:1001-8.
148. Gelbmann CM, Rummele P, Wimmer M, et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol 2007;102:1221-9.
149. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: An evaluation of a modified scoring system. J Hepatol 2000;33:537-42.
150. Bjornsson E., Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature. Hepatology 2007;45:1547-54.
151. Polter DE, Gruhl V, Eigenbrodt EH, Combes B. Beneficial effect of cholestyramine in sclerosing cholangitis. Gastroenteralogy 1980;79:326-33.
152. Tahibian N. Rifampin as antipruritic agent in primary sclerosing cholangitis. Am J Gastroenterol 1989;84:340.
153. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritis: A double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-9.
154. Bergassa NV, Aling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritis of cholestasis. A double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-9.
155. Mayo MJ, Handern I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as first-line treatment for cholestatic pruritis. Hepatology 2007;45:666-74.
156. Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritis in chronic liver disease: A controlled study. Hepatogastroenterology 200;754:1196-9.
157. Leung UC, Wong PY, Roberts RH, Koea JB. Gall bladder polyps in sclerosing cholangitis: Does the 1-cm rule apply? ANZ J Surg 2007;77:355-7.
158. Baron TH. Photodynamic therapy: Standard of care for palliation of cholangiocarcinoma? Clin Gastroenterol Hepatol 2008;6:266-7.